Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8460569 | 0.88 | ALDH1A1 (0.37) | TSHRALDH1A1PTGS2 | |
| SCHEMBL11059074 | 0.86 | ACE2 (0.39) | ALDH1A1 | |
| SCHEMBL12433420 | 0.84 | ALDH1A1 (0.42) | TSHRALDH1A1PTGS2 | |
| SCHEMBL11062410 | 0.82 | — | — | |
| SCHEMBL2920483 | 0.81 | CA12 (0.31) | — | |
| SCHEMBL11056552 | 0.81 | ALDH1A1 (0.33) | ALDH1A1PTGS2 | |
| SCHEMBL11058855 | 0.81 | TSHR (0.34) | TSHRALDH1A1 | |
| SCHEMBL1922340 | 0.80 | CA12 (0.42) | TSHRALDH1A1 | |
| SCHEMBL2739371 | 0.78 | ALDH1A1 (0.35) | ALDH1A1PTGS2 | |
| SCHEMBL11058053 | 0.77 | ACE2 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113337316-A | Preparation method of high-cleanness alcohol ether fuel | 贵州鑫强环保燃料有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-113337316-A | Preparation method of high-cleanness alcohol ether fuel | 贵州鑫强环保燃料有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-7858665-B2 | Drugs for chronic pain | NICOX S.A. (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7812039-B2 | analgesic drug for treating neuropathic pain is selected from gabapentine, norvaline, pregabaline, (S)3-isobutylGABA, arginine, thiocitrulline, agmantine, vigabatrin etc. and a NO donar drugs belonging to the classes of aspirin, ibuprofen, paracetamol, naproxen, diclofenac or flurbiprofen | NICOX S.A. (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | NICOX SA (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7524836-B2 | Nitrooxyderivative steroidal compounds | NICOX S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| US-7378412-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20080113950-A1 | Drugs for chronic pains | NICOX S.A. | 2008-05-15 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-4448587-A | ALKYL NITRATES AND ALKOXYALKYL NITRATES AS ADDITIVES | ETHYL CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239832-A1 | DRUGS FOR CHRONIC PAIN | OPRK1, OPRL1, OPRD1 | TSHR 2361/4885ALDH1A1 671/4885PTGS2 429/4885 |
| US-20070142342-A1 | Pharmaceutical compounds | CYP11B2, CYP11B1, CYP2S1 | TSHR 1073/4885ALDH1A1 392/4885PTGS2 95/4885 |
| US-20080113950-A1 | Drugs for chronic pains | OPRD1, OPRL1, OPRK1 | TSHR 1671/4885ALDH1A1 304/4885PTGS2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.